ArticleBasic and clinical neuroscience2025
Modulatory Effects of CB1 Receptors on Cognitive Performance in Rat Model of Empathic Pain.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cannabinoid receptor type 1 (CB1) is extensively distributed across brain regions that are crucial for emotional processing, social cognition, and anxiety, including the prefrontal cortex, amygdala, and hippocampus. Dysregulation of CB1 receptors (CB1Rs) has been associated with several disorders characterized by impaired empathy, social behavior, and anxiety. Accordingly, this study investigates the modulatory role of CB1Rs in social interaction and anxiety in an empathic pain model in rats. Methods: A total of 48 adult male Wistar rats were used (n=8 for each group). One sibling received formalin injection into the hind paw five times within nine days (demonstrator), and the other siblings reported pain (observer) while being treated with dimethyl sulfoxide (DMSO), the CB1R agonist WIN 55,212-2 (WIN; 3 mg/kg, intraperitoneal), or the CB1R antagonist rimonabant (1 mg/kg intraperitoneal). Treatments were administered intraperitoneally 30 min before behavioral tests conducted on day 10, which were used to assess social behavior and anxiety. Results: Empathic pain can impair social behavior and elicit anxiety-like effects. Rimonabant was effective in ameliorating deficits induced by empathic pain; conversely, WIN did not have a significant effect. Conclusion: CB1Rs play a modulatory role in social contagion. This modulation may provide new therapeutic targets for conditions, such as autism spectrum disorder, schizophrenia, and other psychological disorders characterized by impaired empathy and dysregulated social behavior associated with the CB1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.